Source comparison
Selank Versus Benzodiazepines: a Careful Comparison
Because the title invokes GABA — the benzodiazepines’ own territory — a side-by-side comparison clarifies both what the two have in common and where the analogy breaks down. The comparison should be read as a map of hypotheses and evidence levels, not as a cla
This comparison does not assign a generated winner or score.
- Because the title invokes GABA — the benzodiazepines’ own territory — a side-by-side comparison clarifies both what the two have in common and where the analogy breaks down. The comparison should be read as a map of hypotheses and evidence levels, not as a claim that Selank is an equivalent or interchangeable anxiolytic.
- GABA-A relationship
- Well-defined positive allosteric modulator at the α/γ benzodiazepine site3
- Proposed indirect/allosteric influence on GABA-A affinity; not demonstrated by functional electrophysiology46
- Primary evidence type
- Extensive human RCTs, decades of clinical use
- Small comparator human studies plus Russian preclinical work10
- Sedation
- Common, dose-dependent
- Reported minimal; possible mild stimulant/antiasthenic effect10
- Tolerance / dependence
- Well documented
- Not reported in available studies (but long-term data lacking)
- Other mechanisms
- Essentially GABA-A specific
- Enkephalinase inhibition, serotonergic, BDNF — multi-target789
- Regulatory status
- Approved worldwide as prescription medicines
- Approved in Russia; not FDA/EMA approved for any use11
- Two honest conclusions come out of this table. First, the frequently drawn equation — “Selank is like a benzodiazepine but without the downsides” — is a marketing simplification that runs ahead of the data. It is true that Selank has not shown the sedation and dependence that limit benzodiazepines, and if that holds up it would be genuinely valuable. But the benzodiazepine comparison also implies an efficacy and mechanistic clarity that Selank has not earned: benzodiazepines have an unambiguous, electrophysiologically proven GABA-A mechanism and an enormous human evidence base, and Selank has neither. Second, the very feature that makes Selank attractive — the absence of classical benzodiazepine liabilities — is itself evidence that it is not simply acting at the benzodiazepine site, which points back to the multi-mechanism, indirect picture this article has developed. The lack of sedation is not a free lunch bolted onto a benzodiazepine mechanism; it is a clue that the mechanism is di